Grifols, S.A. (GIKLY)
| Market Cap | 6.94B -24.3% |
| Revenue (ttm) | 8.48B -0.3% |
| Net Income | 516.39M +51.8% |
| EPS | 0.75 +46.1% |
| Shares Out | n/a |
| PE Ratio | 13.44 |
| Forward PE | 9.22 |
| Dividend | 0.04 (0.75%) |
| Ex-Dividend Date | Jul 2, 2026 |
| Volume | 1 |
| Open | 5.13 |
| Previous Close | 5.10 |
| Day's Range | 5.10 - 5.13 |
| 52-Week Range | 5.06 - 7.49 |
| Beta | 1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Grifols
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel... [Read more]
Financial Performance
In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.
Financial numbers in EUR Financial StatementsNews
Grifols completes clinical portion of SPARTA trial
Grifols (GRFS) announced the completion of the clinical portion of SPARTA, its phase 3 outcomes study evaluating the clinical efficacy and safety of two dose regimens of Prolastin-C in patients…
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
BARCELONA, Spain, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the complet...
Grifols says EXCELL Phase 3 trial timeline not ‘new development or a delay’
Grifols (GRFS) issued the following statement on the EXCELL Phase 3 trial timeline: “We have noted the recent Bloomberg article referring to the EXCELL Phase III trial timeline on ClinicalTrials.gov.
Grifols (GRFS) Q2 2026 Earnings Call Transcript
CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.
Grifols Q2 Earnings Call Highlights
Grifols NASDAQ: GRFS said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, im...
Grifols H1 Profit Rises 29%; Backs FY26 Outlook
(RTTNews) - Grifols S.A. (GRFS) on Tuesday reported higher profit for the first half of 2026, supported by growth in its Biopharma business. The company also reaffirmed its full-year guidance.
Grifols Earnings Call Transcript: Q2 2026
Revenue grew 2.6% in H1 2026, led by Biopharma and strong IG demand, with adjusted EBITDA up 2.4% and free cash flow improving by EUR 103 million year-over-year. Albumin in China stabilized, diagnostics advanced with new launches, and the company remains on track for its 2026 guidance.
Grifols Quarterly report: Q2 2026
Grifols has published its Q2 2026 quarterly earnings report on July 28, 2026.
Grifols Earnings release: Q2 2026
Grifols released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Grifols Slides: Q2 2026
Grifols has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Grifols (GRFS) Initiates Phase 3 Trials for Immunoglobulin Treatments
Grifols (GRFS) Initiates Phase 3 Trials for Immunoglobulin Treatments
Grifols doses first patients in two Gamunex-C trials
Grifols (GRFS) announced that the first patients have been dosed in two separate Phase 3 trials aiming to expand the U.S. labels for its signature immunoglobulin therapeutics, Gamunex-C, an intravenou...
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
BARCELONA, Spain, July 16, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced that the fi...
Private clinic Grifols green-lit plasma donors with disease risk, Health Canada finds
The private clinic Grifols repeatedly cleared ineligible donors at risk for Creutzfeldt-Jakob disease and operated dangerously over capacity at a Winnipeg centre, according to a Health Canada inspecti...
Grifols announces U.S. launch of new fibrinogen concentrate
Grifols (GRFS) announced the U.S. launch of its new fibrinogen concentrate. Approved by the FDA in December for the treatment of acute bleeding episodes in pediatric and adult patients with…
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. la...
Grifols price target lowered to EUR 10 from EUR 11 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Grifols (GRFS) to EUR 10 from EUR 11 and keeps a Hold rating on the shares.
Grifols reports Q1 adjusted EBITDA EUR 381M, up 0.8% cc
Reports Q1 total revenue EUR 1.7B, up 3.3% y/y cc. Group profit increased to EUR 73M in the first quarter, up 21.9% year-on-year. Nacho Abia, CEO of Grifols (GRFS), said:…
Grifols says Q1 results support FY26 guidance
11:43 EDT Grifols (GRFS) says Q1 results support FY26 guidance
New conditions imposed on Grifols by Health Canada, CBC News reports
Health Canada has imposed new terms and conditions on all of Grifols (GRFS)’ paid plasma centers following multiple failed inspections that identified recurring systemic deficiencies, including inadeq...
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates
OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people wh...
Grifols rallies after board approves IPO of U.S. Biopharma business
Grifols (GRFS) says its Strategy Committee has proposed, and the board has approved, the initial public offering on the U.S. stock market of a portion of the shares of the…
Grifols to evaluate potential IPO of U.S. Biopharma business
According to a regulatory filing, Grifols (GRFS) reported that, as a consequence of Grifols’ self-sufficiency programs for its Biopharma businesses, its Board of Directors has decided to initiate a pr...
Grifols approves IPO of its US biopharma business
Healthcare company Grifols said on Tuesday it has approved a U.S. initial public offering of its U.S. biopharma business.
Grifols price target lowered to EUR 11 from EUR 12 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Grifols (GRFS) to EUR 11 from EUR 12 and keeps a Hold rating on the shares.